EFG Asset Management North America Corp. Purchases 56,758 Shares of Insmed Incorporated (NASDAQ:INSM)

EFG Asset Management North America Corp. boosted its holdings in Insmed Incorporated (NASDAQ:INSM) by 111.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 107,625 shares of the biopharmaceutical company’s stock after buying an additional 56,758 shares during the period. Insmed makes up 1.0% of EFG Asset Management North America Corp.’s investment portfolio, making the stock its 13th largest position. EFG Asset Management North America Corp.’s holdings in Insmed were worth $7,431,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC grew its stake in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares during the period. V Square Quantitative Management LLC boosted its holdings in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management bought a new stake in Insmed in the 4th quarter worth approximately $47,000. Smartleaf Asset Management LLC raised its stake in Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in Insmed during the 4th quarter valued at $86,000.

Insmed Trading Down 0.7 %

Shares of INSM stock opened at $79.38 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a fifty day simple moving average of $77.64 and a two-hundred day simple moving average of $73.84. The firm has a market capitalization of $14.37 billion, a PE ratio of -14.20 and a beta of 1.28. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, February 21st. Royal Bank of Canada restated an “outperform” rating and set a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. Morgan Stanley increased their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Guggenheim restated a “buy” rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Finally, Bank of America upped their target price on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a report on Thursday, March 20th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $94.00.

Insider Buying and Selling at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the sale, the chief executive officer now owns 334,186 shares in the company, valued at $25,742,347.58. The trade was a 5.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sara Bonstein sold 1,066 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.72, for a total value of $67,925.52. Following the transaction, the chief financial officer now owns 118,863 shares of the company’s stock, valued at approximately $7,573,950.36. The trade was a 0.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 550,957 shares of company stock valued at $42,992,528 in the last three months. 4.60% of the stock is currently owned by corporate insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.